The Quantellect read.As of Nov 19, 2026, 5 active firms cover Zentalis Pharmaceuticals Llc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $8.00 to $11.00, so the covering firms are broadly aligned. The average target of $9.25 sits 575% above the current $1.37. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.48 next quarter toward $-1.52 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$9.25
+575.2% upside
Average target across 4 active firms as of Nov 19, 2026 vs $1.37 current
Highest Target$11.00
Average Target$9.25
Lowest Target$8.00
Detailed analyst forecasts for ZNTL
Showing 1–4 of 4 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate ZNTL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ZNTL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.48
Range $-0.63 – $-0.40 · 4 analysts
Next period, 4 analysts expect Zentalis Pharmaceuticals Llc to earn $-0.48 a share (range $-0.63 – $-0.40), versus — a year earlier. Full-year consensus is $-1.75, growing to $-1.52 the year after.
REVENUE · NEXT QUARTER
$133.3K
Range $0 – $800.0K · 4 analysts
Revenue is expected to reach $133.3K (range $0 – $800.0K). Full-year consensus is $0, rising to $1.6M next year.
Top analysts covering Zentalis Pharmaceuticals Llc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ZNTL.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$10.00+629.9% to target
Overall win rate
53%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$10.00+629.9% to target
Overall win rate
45%
+ Follow
#3
Andrew Berens
Leerink Partners · Rank #162
Neutral
$5.00+265.0% to target
Overall win rate
53%
+ Follow
#4
Graig Suvannavejh
Mizuho · Rank #239
Buy
$7.00+410.9% to target
Overall win rate
40%
+ Follow
#5
Andres Y. Maldonado
HC Wainwright & Co. · Rank #288
Buy
$10.00+629.9% to target
Overall win rate
39%
+ Follow
ZNTL stock forecast FAQ
What is ZNTL's average 12-month price target?+
The 4 active firms with a live target average $9.25 for Zentalis Pharmaceuticals Llc over the next 12 months, ranging from a $11.00 high to a $8.00 low, as of Nov 19, 2026.
Is ZNTL stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ZNTL?+
The Street-high target is $11.00, and the Street-low is $8.00 (Leerink Partners). The average of all 4 active-firm targets is $9.25.
How many active Wall Street firms cover ZNTL?+
5 active firms have a recognized rating on Zentalis Pharmaceuticals Llc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ZNTL?+
Among analysts who currently cover ZNTL, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $10.00 target.
What is Zentalis Pharmaceuticals Llc's projected EPS for next quarter?+
The consensus estimate is $-0.48 per share (range $-0.63 – $-0.40) across 4 analysts. Full-year EPS is projected at $-1.75, rising to $-1.52 the following year.
How much revenue is Zentalis Pharmaceuticals Llc expected to report next quarter?+
Consensus revenue is $133.3K (range $0 – $800.0K). Full-year revenue is projected at $0, growing to $1.6M next year.
Have analysts been upgrading or downgrading ZNTL lately?+
As of Nov 19, 2026, 5 of 5 active firms rate ZNTL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ZNTL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.